13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001974915
Total reported value
$4.3B
$4.3B
73 檔
10.4%
The Q4 2024 SEC filing reveals that Vestal Point Capital, LP held a total portfolio value of $4.3B, covering 73 public equity positions.
During Q4 2024, Vestal Point Capital, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including JAZZ, CYTK, MRK) accounted for 10.4% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 7.12% | — | +8.33% | |
| 2 | CYTK | Cytokinetics Inc | Stock-Healthcare | 6.55% | -0.55% | EXIT | |
| 3 | MRK | Merck & Co. Inc. | Stock-Healthcare | 4.72% | — | — | |
| 4 | ASND | Ascendis Pharma A/S | Stock-Other | 4.24% | -2.40% | EXIT | |
| 5 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.74% | — | +100.00% | |
| 6 | INSM | Insmed Inc | Stock-Healthcare | 3.68% | +0.62% | NEW | |
| 7 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 3.35% | +2.41% | +115.00% | |
| 8 | QURE | uniQure N.V. | Stock-Other | 3.17% | +0.85% | -36.32% | |
| 9 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.82% | -0.68% | EXIT | |
| 10 | NUVL | Nuvalent Inc-a | Stock-Other | 2.78% | -1.38% | EXIT | |
| 11 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.77% | — | +50.00% | |
| 12 | VERA | Vera Therapeutics Inc | Stock-Other | 2.70% | -1.54% | EXIT | |
| 13 | ✓ | Immatics NV | Stock-Other | 2.65% | -0.24% | +67.33% | |
| 14 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.40% | -1.04% | EXIT | |
| 15 | GERN | Geron CORP | Stock-Other | 2.31% | -0.11% | EXIT | |
| 16 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 2.22% | — | +4.50% | |
| 17 | ACLXGBX | Arcellx Inc | Stock-Other | 2.16% | — | -29.63% | |
| 18 | SNY | Sanofi-adr | Stock-Healthcare | 2.14% | +0.10% | +400.00% | |
| 19 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 2.01% | — | +233.33% | |
| 20 | SVRA | Savara Inc | Stock-Other | 1.96% | -0.01% | +33.19% | |
| 21 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.88% | -0.05% | -1.82% | |
| 22 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.87% | — | — | |
| 23 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 1.85% | — | — | |
| 24 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.80% | — | — | |
| 25 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.74% | +0.36% | +216.67% | |
| 26 | GMED | Globus Medical Inc - A | Stock-Healthcare | 1.59% | +0.10% | — | |
| 27 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.39% | — | +172.15% | |
| 28 | ✓ | Nyxoah S A | Stock-Other | 1.39% | -0.04% | — | |
| 29 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.36% | — | — | |
| 30 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.23% | — | — | |
| 31 | LQDA | Liquidia CORP | Stock-Other | 1.23% | — | +17.33% | |
| 32 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.08% | — | -42.40% | |
| 33 | URGN | UroGen Pharma Ltd. | Stock-Other | 1.03% | -0.07% | EXIT | |
| 34 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.92% | — | +280.00% | |
| 35 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.88% | — | — | |
| 36 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.84% | -0.28% | — | |
| 37 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.82% | — | +650.00% | |
| 38 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.82% | -0.06% | EXIT | |
| 39 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.73% | +0.62% | +67.06% | |
| 40 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.71% | — | +11.37% | |
| 41 | SLDB | Solid Biosciences Inc | Stock-Other | 0.68% | -0.51% | +1.79% | |
| 42 | A | Agilent Technologies Inc | Stock-Healthcare | 0.60% | — | -25.00% | |
| 43 | APLT | Applied Therapeutics Inc | Stock-Other | 0.58% | — | +904.37% | |
| 44 | PRGO | Perrigo Company plc | Stock-Healthcare | 0.57% | — | — | |
| 45 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.54% | +1.74% | +14.12% | |
| 46 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.47% | -0.25% | +41.18% | |
| 47 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 0.47% | — | — | |
| 48 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.46% | -1.09% | EXIT | |
| 49 | VYGR | Voyager Therapeutics Inc | Stock-Other | 0.41% | -0.11% | +151.02% | |
| 50 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.41% | — | -12.20% |
According to official SEC Form 13F filings, Vestal Point Capital, LP reported a total U.S. public equity portfolio value of $4.3B across 73 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q4 2024, Vestal Point Capital, LP's top holdings by market value included JAZZ (7.1%)、CYTK (6.5%)、MRK (4.7%). The largest single position, JAZZ, represented 7.1% of total portfolio value.
In Q4 2024, Vestal Point Capital, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.